April 18th 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
Employers are Concerned about Specialty Drug Costs
November 3rd 2022Wendy Barnes and Mark Campbell of RxBenefits discuss the company’s survey, which finds employers are curious about solutions to manage both specialty drug spend and the potential volatility that comes with employees who may be diagnosed with cancer and other high-dollar conditions.